- Home
- / Royalty Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Royalty Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$27.1
2024-10-29
Market Capitalization
$16.2 B
2024-10-29
Revenue
$2.4 B
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.1B | 2.3B | 2.2B | 2.4B | 2.3B | 2.4B |
| General and administrative expense | 181.7M | 182.8M | 227.3M | 249.7M | 236.7M | 573.5M |
| Operating expense total | 246.8M | 404.4M | 301.7M | 238.7M | 1.0B | |
| Depreciation and amortization | 23.1M | 23.0M | 5.7M | |||
| EBIT | 1.6B | 1.4B | 307.1M | 1.5B | 1.3B | 1.6B |
| EBIT margin, % | 75.2% | 13.7% | 63.4% | 57.1% | 65.6% | |
| Investment income | 72.3M | 29.6M | ||||
| Interest income | 47.3M | |||||
| Interest expense | 157.1M | 166.1M | 188.0M | 187.2M | 159.6M | |
| Pre tax profit | 1.7B | 1.2B | 230.1M | 1.7B | 1.3B | 1.3B |
| Net Income | 1.7B | 1.2B | 230.1M | 1.7B | 1.3B | 1.3B |
| EPS | 0.1 | 2.5 | 1.9 | 1.8 |